Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
See More
BD Horizon™ BV510 Mouse Anti-Human CD90
クローン 5E10 (RUO)
Flow cytometric analysis of CD90 expression on human HEL cells. HEL cells (Human erythroleukemia cell line; ATCC Cat. No. TIB-180™) were stained with BD Horizon™ BV510 Mouse Anti-Human CD90 antibody (Cat. No. 563070, solid line histogram) or a BD Horizon™ BV510 BV510 Mouse IgG1, k Isotype Control (Cat. No. 562946; dashed line histogram). Flow cytometric fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable cells. Flow cytometry was performed using a BD™ LSR II Flow Cytometry System.
Flow cytometric analysis of CD90 expression on human HEL cells. HEL cells (Human erythroleukemia cell line; ATCC Cat. No. TIB-180™) were stained with BD Horizon™ BV510 Mouse Anti-Human CD90 antibody (Cat. No. 563070, solid line histogram) or a BD Horizon™ BV510 BV510 Mouse IgG1, k Isotype Control (Cat. No. 562946; dashed line histogram). Flow cytometric fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable cells. Flow cytometry was performed using a BD™ LSR II Flow Cytometry System.
製品詳細
BD Horizon™
THY1; Thy-1 antigen; Thy-1 membrane glycoprotein
Human (QC Testing)
Mouse BALB/c IgG1, κ
Human HEL Cell Line
Flow cytometry (Routinely Tested)
5 µl
V M07, BP222; VI BP28, E046
AB_2737987
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
RUO
Preparation and Storage
The antibody was conjugated with BD Horizon™ BV510 under optimum conditions, and unconjugated antibody and free BD Horizon™ BV510 were removed. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- An isotype control should be used at the same concentration as the antibody of interest.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Brilliant Violet™ 510 is a trademark of Sirigen.
関連製品
Stain Buffer (FBS) RUO
サイズ
500 ML
カタログ番号
554656
BV510 Mouse IgG1, k Isotype Control RUO
サイズ
50 µg
カタログ番号
562946
563070 Rev. 1
抗体の詳細
5E10
The 5E10 monoclonal antibody specifically binds to human CD90 which is also known as Thy-1. CD90 is a 25-35 kDa glycophosphatidylinositol-anchored membrane glycoprotein of the Ig superfamily that is expressed on 1-4% of human fetal liver cells, cord blood cells, and bone marrow cells. The anti-CD90 antibody binds to a subset of immature CD34+ cells and a distinct subset of mature CD34- cells that are CD3+CD4+. The CD90+CD34+ population is highly enriched for cells capable of long-term culture. The anti-CD90 antibody is useful for enriching high proliferative potential colony-forming cells (HIPP-CFC) that are primative progenitor cells.
The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon™ Brilliant Violet™ family of dyes. With an Ex Max of 405-nm and Em Max at 510-nm, BD Horizon™ BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50-nm) filter set. BD Horizon™ BV510 conjugates are useful for the detection of dim markers off the violet laser.
563070 Rev. 1
フォーマットの詳細
BV510
The BD Horizon Brilliant Violet™ 510 (BV510) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye with an excitation maximum (Ex Max) at 327-nm / 405-nm and an emission maximum (Em Max) at 512-nm. BV510, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 510-nm (e.g., a 525/50 bandpass filter). The dye can be excited by the UV (355-nm) laser resulting in cross-laser excitation and spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
BV510
327 nm, 405 nm
512 nm
563070 Rev.1
引用＆参考文献
View product citations for antibody "563070" on CiteAb
Development References (5)
-
Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A. 1992; 89(7):2804-2808. (Biology). View Reference
-
Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med. 1993; 177(5):1331-1342. (Immunogen: Flow cytometry, Immunoprecipitation, Western blot). View Reference
-
Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:1-1182.
-
Lansdorp PM, Thomas TE. AP Gee, ed. Bone Marrow Processing and Purging. Boca Raton FL: CRC Press; 1991.
-
Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995.
563070 Rev. 1
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.